PHIA Koninklijke Philips N.V.

Philips and Leeds Teaching Hospitals NHS Trust to set new standards for specialist integrated cardiac care

Philips and Leeds Teaching Hospitals NHS Trust to set new standards for specialist integrated cardiac care

June 25, 2020 

Seven-year agreement puts patients at heart of service design to support increased excellence across specialist care, research and local care provision

Amsterdam, the Netherlands and Guildford, UK – (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Leeds Teaching Hospitals NHS Trust today announced a seven-year managed service agreement to deliver on the Trusts’ vision to set new standards of excellence for cardiac care in the UK and globally. The partnership will combine the latest innovations in technology for integrated cardiovascular solutions to deliver on the quadruple aim: better health outcomes, lower cost of care, and an improved experience for patients and staff. The service improvement program will support the co-design of new patient pathways and workflows, all with the aim of delivering the best care experience for patients.

“The Cardiology team at Leeds Teaching Hospitals are very proud of the quality of cardiac care we are able to deliver for our patients,” said Dr Chris Pepper, Clinical Director for Cardiology at Leeds Teaching Hospitals NHS Trust. “We see this partnership as a hugely exciting and positive opportunity to improve this further. We look forward to being able to provide state-of-the-art cardiac imaging as part of a highly efficient and forward-looking cardiology service for the people of Leeds and West Yorkshire. We also look forward to a positive and collaborative working relationship with Philips.”

The agreement includes six fully featured interventional cardiac suites based on the Philips Azurion platform, including two specialized electrophysiology suites and a structural heart suite, as well as advanced patient monitoring and ultrasound systems. The Azurion platform provides an intuitive, seamless approach for minimally invasive procedures that will support Leeds’ clinicians to focus on treating the patient, and its administrators as they strive to improve productivity and efficiency through intelligent resource management.

Dr Pepper continued, “We are now working through the backlog of patients and other challenges created by the COVID-19 pandemic. We need to keep services running and have been supported through our partnership with Philips including in reorganizing lab allocations and maintaining patient flow, which has been of substantial benefit. Our cath labs are an essential part of our operations, so when two of our systems recently needed urgent repair, we were happy that Philips was able to resolve the issues without impact on our daily workflow. Our state-of-the-art ultrasound systems have also helped us maintain efficiency after the first wave of COVID-19 patients and will help streamline and facilitate further recovery.”

"Cardiovascular disease is one of the world’s leading causes of death [1] and in the UK we are now seeing more people dying of heart disease at younger ages than in previous years,” said Neil Mesher, General Manager of Philips UK & Ireland. “The COVID-19 pandemic has shown what we can achieve when we combine our collective resources to combat an urgent, complex challenge. It’s with this spirit that we look forward to working side-by-side with Leeds Teaching Hospitals NHS Trust to improve the region’s cardiac health.”

Leeds Cardiac Clinical Services Unit sees over 25,000 patients a year and offers specialist cardiology services to a regional UK population of over 5.4 million across West Yorkshire. As both a local care provider and international specialism centre, the Trust operates an aspirational international innovation programme that not only benefits the local population but also the global cardiology community by developing cutting-edge techniques to meet challenging patient presentations. With both local and international objectives, Leeds has decided to work in partnership with Philips on a long-term basis to ensure these aspirations are met.

[1]

For further information, please contact:

Mark Groves

Philips Global Press Office

Tel:

Email:

Twitter:

Emily Wells-Burr

Philips UK & Ireland

Tel: 5

Email:

About Royal Philips

Royal Philips (NYSE: PHG, AEX: PHIA) is a leading health technology company focused on improving people's health and enabling better outcomes across the health continuum from healthy living and prevention, to diagnosis, treatment and home care. Philips leverages advanced technology and deep clinical and consumer insights to deliver integrated solutions. Headquartered in the Netherlands, the company is a leader in diagnostic imaging, image-guided therapy, patient monitoring and health informatics, as well as in consumer health and home care. Philips generated 2019 sales of EUR 19.5 billion and employs approximately 81,000 employees with sales and services in more than 100 countries. News about Philips can be found at .



Attachments

EN
25/06/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Koninklijke Philips N.V.

 PRESS RELEASE

Philips launches RADIQAL study to generate real-world evidence for new...

Philips launches RADIQAL study to generate real-world evidence for new ultra-low X-ray dose technology in coronary procedures May 20, 2025 Prospective, randomized, unblinded, comparative, international, multi-center clinical investigation824 patients across 6 hospitals in Spain, Czech Republic, Denmark and the USPrimary objective is to demonstrate that the new technology can reduce overall patient radiation dose without affecting coronary procedure performance. Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the launch of the (R...

 PRESS RELEASE

Philips launches real-time 3D intracardiac imaging in Europe, expandin...

Philips launches real-time 3D intracardiac imaging in Europe, expanding access to minimally invasive heart procedures May 19, 2025 VeriSight Pro 3D ICE catheter is a pioneering innovation — a miniaturized ultrasound probe embedded at the tip of a thin, steerable catheter, navigated through the vascular system into the heart chambers to deliver high-quality 2D and 3D images in real timeCatheter offers enhanced procedural guidance without the need for general anesthesia, supporting more efficient and patient-friendly care for structural heart disease Amsterdam, the Netherlands – (NYSE: PHG...

 PRESS RELEASE

Philips successfully prices offering of Notes for EUR 1 billion to be ...

Philips successfully prices offering of Notes for EUR 1 billion to be used for repayment of existing debt and to finance eligible green projects May 15, 2025 Amsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, today announced the successful pricing of its offering of EUR 500 million fixed rate notes due 2030 and EUR 500 million fixed rate notes due 2035 (the “Notes”) under its European Medium Term Note (EMTN) program. The net proceeds will be used for general corporate purposes, the repayment of 2026 debt maturities, and to refinance or finance any ...

 PRESS RELEASE

Philips Future Health Index 2025: AI poised to transform global health...

Philips Future Health Index 2025: AI poised to transform global healthcare, urging leaders to act now May 15, 2025AI has the power to cut care delays and manage data overload, but trust gaps among clinicians and patients threaten to slow adoption and impactAmsterdam, the Netherlands – (NYSE: PHG, AEX: PHIA), a global leader in health technology, , highlighting the growing strain on global healthcare systems. The FHI 2025 Report, the largest global survey of its kind analyzing key concerns of healthcare professionals and patients, indicates AI holds promise for transforming care delivery. H...

Koninklijke Philips N.V.: 1 director

A director at Koninklijke Philips N.V. bought 8,176 shares at 24.410USD and the significance rating of the trade was 78/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two yea...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch